Literature DB >> 12820078

Does anticoagulation do more harm than good?: A comparison of patients treated without prophylaxis and patients treated with low-dose warfarin after total knee arthroplasty.

Raymond A Sachs1, Jennifer H Smith, Mary Kuney, Liz Paxton.   

Abstract

A cohort of 785 patients treated without any form of thromboprophylaxis was compared with an identical group of 957 patients treated with 6 weeks of low-dose warfarin. All complications seen within 90 days of surgery were recorded. The control group had a total complication rate of 2.2%, with a death rate from thromboembolic disease of 0.0% and a total death rate of 0.2%. The warfarin group had a total complication rate of 4.7%, with a death rate from thromboembolic disease of 0.0% and a total death rate of 0.1%. Both deaths in the control group were from cardiac disease, while the death in the warfarin group was due to a massive gastrointestinal bleeding. The warfarin group had twice the infection rate of the control group.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12820078     DOI: 10.1016/s0883-5403(03)00071-8

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  18 in total

1.  CORR Insights®: Venous Thromboembolism Prophylaxis After TKA: Aspirin, Warfarin, Enoxaparin, or Factor Xa Inhibitors?

Authors:  Daniel R Whiting
Journal:  Clin Orthop Relat Res       Date:  2017-06-27       Impact factor: 4.176

2.  Thromboembolic disease after knee arthroplasty is rare in Southern Iran.

Authors:  G Hossain Shahcheraghi; Mahzad Javid; Mohammad M Arasteh
Journal:  J Orthop       Date:  2014-01-31

Review 3.  Real-world effectiveness and safety of pharmacological thromboprophylaxis in patients undergoing primary total hip and knee arthroplasty: A narrative review.

Authors:  Astrid Blicher Schelde; Astrid Eliasen; Jonas Bjerring Olesen; Thomas Bo Jensen; Espen Jimenez-Solem
Journal:  J Orthop       Date:  2019-11-12

4.  Thrombin generation profiles as predictors of symptomatic venous thromboembolism after trauma: A prospective cohort study.

Authors:  Myung S Park; Grant M Spears; Kent R Bailey; Ailing Xue; Michael J Ferrara; Amy Headlee; Sabtir K Dhillon; Donald H Jenkins; Scott P Zietlow; William S Harmsen; Aneel A Ashrani; John A Heit
Journal:  J Trauma Acute Care Surg       Date:  2017-09       Impact factor: 3.313

5.  Comparison of postoperative complications after total hip arthroplasty among patients receiving aspirin, enoxaparin, warfarin, and factor Xa inhibitors.

Authors:  Perez Agaba; Beau J Kildow; Herman Dhotar; Thorsten M Seyler; Michael Bolognesi
Journal:  J Orthop       Date:  2017-08-14

Review 6.  Centers for Disease Control and Prevention 2017 Guidelines for Prevention of Surgical Site Infections: Review and Relevant Recommendations.

Authors:  K Keely Boyle; Sridhar Rachala; Scott R Nodzo
Journal:  Curr Rev Musculoskelet Med       Date:  2018-09

7.  Aspirin: an alternative for pulmonary embolism prophylaxis after arthroplasty?

Authors:  Ibrahim J Raphael; Eric H Tischler; Ronald Huang; Richard H Rothman; William J Hozack; Javad Parvizi
Journal:  Clin Orthop Relat Res       Date:  2014-02       Impact factor: 4.176

8.  VKORC1 variant genotypes influence warfarin response in patients undergoing total joint arthroplasty: a pilot study.

Authors:  Alejandro González Della Valle; Saurabh Khakharia; Charles J Glueck; Nicole Taveras; Ping Wang; Robert N Fontaine; Eduardo A Salvati
Journal:  Clin Orthop Relat Res       Date:  2008-11-26       Impact factor: 4.176

9.  Symptomatic pulmonary embolus after joint arthroplasty: stratification of risk factors.

Authors:  Javad Parvizi; Ronald Huang; Ibrahim J Raphael; William V Arnold; Richard H Rothman
Journal:  Clin Orthop Relat Res       Date:  2013-11-22       Impact factor: 4.176

Review 10.  Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty.

Authors:  Nigel E Sharrock; Alejandro Gonzalez Della Valle; George Go; Stephen Lyman; Eduardo A Salvati
Journal:  Clin Orthop Relat Res       Date:  2008-02-10       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.